Regulatory spotlight and what it could mean for Morgan Stanley (MS)

Morgan Stanley (MS) is back in the headlines after the US Financial Industry Regulatory Authority opened a preliminary investigation into compliance and regulatory practices in the bank’s Budapest investment banking program.

The inquiry focuses on how the Budapest office has handled regulatory requirements, which is drawing attention from investors who watch Morgan Stanley’s risk profile and operational controls as closely as its earnings and deal pipeline.

While the Finra inquiry has added a regulatory question mark, the stock’s recent 30-day share price return of 14.14% and 1-year total shareholder return of 63.79% suggest investors have, so far, treated this as a contained issue within a longer period of strong wealth creation.

If this investigation has you reassessing your exposure to large financial stocks, it can be useful to compare opportunities using a focused list such as 19 top founder-led companies

After a 63.79% 1 year total return, solid revenue and net income growth, and a share price not far from the average analyst target, the key question is whether Morgan Stanley is still mispriced or if markets are already accounting for potential future growth.

Most Popular Narrative: 1% Undervalued

The latest widely followed narrative pegs Morgan Stanley’s fair value at about $190.33, just above the last close of $189.25. This frames a very tight valuation gap.

The analysts have a consensus price target of $190.33 for Morgan Stanley based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $221.0, and the most bearish reporting a price target of just $153.0.

Want to see what is driving that narrow fair value range? The narrative leans heavily on steady top line growth, firmer margins and a richer future earnings multiple. The interplay between those assumptions is where the real story sits.

Result: Fair Value of $190.33 (ABOUT RIGHT)

However, that tight fair value gap can quickly move if regulatory costs rise or if competition in low fee wealth products pressures margins more than analysts expect.

Another Angle on Value

Analysts have framed Morgan Stanley as roughly fairly priced using their earnings based model, but the SWS DCF model tells a different story. On that view, the stock at $189.25 sits above an estimated cash flow value of $180.19, which points to a potential overvaluation instead of a small discount. For an investor, that raises a simple question: which set of assumptions feels more realistic for the next few years?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Morgan Stanley for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With mixed signals across valuation models and sentiment, this is a moment to review the full data set yourself, determine where you stand, and then weigh the 4 key rewards and 2 important warning signs

Looking for more investment ideas?

If you stop here, you only see part of what is possible. Use the tools available, compare ideas side by side, and give yourself a broader opportunity set.

• Spot potential bargains early by checking companies highlighted in the screener containing 25 high quality undiscovered gems.
• Strengthen your core holdings by reviewing stocks with a solid balance sheet and fundamentals stocks screener (46 results).
• Lock in more consistent cash flow from equities by scanning for 13 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.